Conclusion
Three open-label clinical trials and one double-blind, split-face controlled study (Rakuto Bio Technologies) in subjects with Fitzpatrick skin types II-IV have confirmed the tolerability of Elure. In all clinical studies conducted with Elure, significant improvement in tone, evenness, and dyspigmentation were achieved in most subjects within 1 month of use. Elure has been shown to be better tolerated and more effective than 2% hydroquinone. However, more studies are needed to compare the product against stronger concentrations of hydroquinone and other existing treatments, as well as to demonstrate its effectiveness in the treatment of other pigmentary conditions in a broader range of patients. The use of Elure in a combination skin care regimen with hydroquinone and glycolic acid has not been studied, but there is no reason to believe that these products would be incompatible. In fact, a glycolic cleanser that lowers the pH of the skin prior to application could theoretically enhance the efficacy of the product.
Dr. Baumann is on the advisory board of Syneron, the manufacturer of Elure.